Press and Announcements

Praetego’s progress is routinely updated as we strive to enter clinical trials.
Please check back frequently for news, announcements, and events.


Praetego awarded $2.5M from NIA to continue Alzheimer’s work

October 4, 2022

Praetego Inc, a pharmaceutical company committed to protecting patients from neurodegenerative diseases related to aging, is pleased to announce a $2.5M STTR award from the National Institute of Aging (NIA). The Phase 2 award advances Praetego’s lead candidate, PTG-630, against Alzheimer’s disease (AD).


Praetego Wins RESI Longevity Innovator’s Pitch Challenge

September 30, 2021

Praetego wins Innovator’s Pitch Challenge at RESI Longevity


Life Science Nation Interview

July 14, 2021

After being a winner in the Digital RESI June Innovator’s Pitch Challenge, Praetego’s CEO Pepper Landson is interviewed by Life Science Nation to tell her story.


Praetego Receives Third Grant from the NIH

June 1, 2021

Praetego Inc, a preclinical stage pharmaceutical company developing novel candidates against chronic diseases of aging, is pleased to announce an award of a $458K grant to study the Amadorin candidates for the treatment of Alzheimer’s Disease.

View press release here.


2021 Health Innovation Hub: Life Science Cohort

April 26, 2021

Praetego’s CEO, Pepper Landson, is honored to be invited to Springboard Enterprises’ 2021 Health Innovation Hub: Life Science cohort.


NIH Phase 2 STTR Funding Award

September 30, 2020

Praetego Inc. is pleased to announce the approval of a multi-year $2.1M STTR grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health. The award advances the Company’s proprietary small molecules for treatment of Diabetic Peripheral Neuropathy (DPN).


Praetego to present at the Venture Connect Summit in Raleigh NC

March 1, 2020

Praetego will showcase their candidates as potential disease modifying drugs against serious diabetic complications, starting with Diabetic Peripheral Neuropathy. The Amadorins are novel small molecules developed by Praetego scientists and designed from a clinically proven prototype.


BIO CEO interview

February 10, 2020

Praetego co-founder and CEO Pepper Landson sat down with Proactive’s Christine Corrado at BIO CEO in New York.


Phase 2 grant submitted to NIH/NIDDK

January 2, 2020

After a successful conclusion of the Phase 1 NIDDK grant, Praetego submits a Phase 2 SBIR/STTR grant to continue preclinical development of novel Amadorins against Diabetic Peripheral Neuropathy. This award would provide preclinical proof of concept in multiple animal models of Type 1 and Type 2 diabetic neuropathy.